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Surgical staging, including lymph node sampling, for endometrial cancer was adopted by the International Federation of
Gynecology and Obstetrics (FIGO) in 1988 based on reports demonstrating diagnostic and therapeutic advantages. This review
focuses on the incidence of lymph node metastasis, risk factors for lymph node involvement, the eﬀect of lymph node metastasis
on prognosis, the therapeutic eﬀect and diagnostic usefulness of lymphadenectomy, risks of lymph node dissection, and future
directions in surgical staging of endometrial cancer. Surgical staging identiﬁes most patients with extrauterine disease as well
as uterine risk factors for recurrence, thereby allowing for a more informed approach to postoperative adjuvant therapy.
Lymphadenectomy as a part of surgical staging is not required in patients assessed intraoperatively to be at low risk for lymph
node metastasis (<2cm grade 1 tumors with superﬁcial myometrial invasion), however, a systematic lymph node dissection
should be performed in most other patients with endometrial cancer. In the future, molecular markers may be useful to predict
preoperatively tumor aggressiveness and lymph node metastasis. It is hoped that an approach of surgical staging with selective
lymph node dissection will improve survival and spare patients additional surgical complications or unnecessary postoperative
exposure to radiation and/or chemotherapy.
1.Introduction
Endometrial cancer is the most common gynecologic malig-
nancy in the United States with an estimated 43,470 new
cases and 7,950 cancer-related deaths in 2010 [1]. Most
patients are diagnosed with uterine-conﬁned disease, which
can usually be cured by surgery alone. The presence of
extrauterine disease signiﬁcantly aﬀects recurrence rates and
survival, which emphasizes the importance of identiﬁcation
of sites of disease spread and provision of appropriate
adjuvant postoperative therapy.
In 1987, the Gynecologic Oncology Group (GOG)
published results of Protocol 33, which investigated the
usefulness of surgical staging in patients with endometrial
cancer clinically conﬁned to the uterus. This study found
that 22% of patients had disease spread outside the uterus,
including disease spread to pelvic lymph nodes in 9% and
para-aortic lymph nodes in 5% [2]. In response to this paper
and others, the International Federation of Gynecology and
Obstetrics (FIGO) changed to a surgical staging system for
endometrial cancer in 1988 [3].
Sincetheestablishmentofsurgicalstagingasthestandard
initial step in the management of most patients with
endometrial cancer, the performance of pelvic and para-
aortic lymphadenectomy as part of surgical staging has
increased due to reports showing diagnostic and therapeutic
advantages [4, 5]. Subsequently, in 2006, the American
Congress of Obstetricians and Gynecologists (ACOG) rec-
ommended surgical staging, including lymph node sam-
pling, for most women with endometrial cancer except
young women desiring fertility preservation and women
at increased risk of mortality secondary to comorbidities
[6]. Despite these recommendations, lymph node dissection
as a part of endometrial cancer staging, especially in “low2 International Journal of Surgical Oncology
risk” patients, is still controversial and staging practices
vary widely based upon individual physician and institu-
tional practices. In a recent survey of members of the
Society of Gynecologic Oncologists, 35%, 66%, and 90% of
respondents routinely performed a lymph node dissection
as part of endometrial cancer staging in grade 1, 2, and 3
tumors, respectively. In addition, most members (53% of
respondents) did not use intraoperative frozen section to
guide decisions about lymph node dissection [7].
This paper on lymph node dissection as a component
of surgical staging of endometrial cancer will focus on the
incidence of lymph node metastasis, risk factors for lymph
node involvement, the eﬀect of lymph node metastasis on
prognosis, the therapeutic eﬀect of lymph node dissection,
and the diagnostic usefulness of lymph node dissection in
directing postoperative adjuvant therapy.
2. Risk Factors for
LymphNode Metastases
Tumor grade and depth of myometrial invasion appear to be
the two most important factors in determining the risk for
lymph node metastasis. In GOG Protocol 33, Creasman et al.
reported that the overall incidence of lymph node metastasis
in clinically uterine-conﬁned endometrial cancer was about
3% in grade 1, 9% in grade 2, and 18% in grade 3 tumors.
Less than 5% of patients with <50% myometrial invasion
had lymph node metastasis compared with about 20% of
patients with >50% myometrial invasion. Pelvic lymph node
metastases were present in less than 5% of grade 1 and 2
tumors with <50% myometrial invasion, in about 15% of
grade 1 and 2 tumors with >50% myometrial invasion or
grade3tumorswith<50%myometrialinvasion,andinmore
than 40% of grade 3 tumors with >50% myometrial invasion
[2]. Boronow et al. noted that patients with outer one-third
myometrial invasion had a 25% incidence of pelvic lymph
node metastasis and a 17% incidence of para-aortic lymph
node metastasis compared to only a 1% incidence of a lymph
node metastasis in patients without myometrial invasion
[8]. Chi et al. reporting on the incidence of lymph node
metastasis in patients with surgically staged endometrioid
endometrial cancer conﬁrmed that as tumor grade increased
the risk of myometrial invasion also increased [9]. In their
series, no patient with grade 1 tumor on ﬁnal pathology and
only 2% of patients with no myometrial invasion had lymph
node metastasis.
The incidence of lymph node metastasis also correlates
with tumor size (<2cm, 4%; >2cm, 15%; entire cavity,
35%) [10, 11]. Schink et al. from Northwestern and Mariani
et al. from the Mayo Clinic reported that no patient with
endometrial grade 1 or 2 tumors and <50% myometrial
invasion had lymph node metastasis when the tumor size
was ≤2cm [10, 11]. Cervical involvement is associated
with about a 15% risk of lymph node metastasis [12].
Extrauterine spread of diseases increases the risk of lymph
node metastasis. Adnexal metastasis increases the risk for
pelvic and para-aortic nodal metastasis to 32% and 20%,
respectively[12].Positiveperitonealcytologyhasbeenfound
to be associated with deep myometrial invasion, cervical
involvement, adnexal spread, and lymph node metastasis
[13]. In a prospective evaluation of peritoneal cytology
in patients with clinical stage I endometrial cancer who
underwent primary surgical therapy at Northwestern, we
foundthatpatientswithmalignantpelvicwashingsoftenhad
other poor prognostic factors, including deep myometrial
invasion in 37%, grade 3 tumors in 37%, and positive lymph
nodes in 17% [14].
3.PrognosticImportance of
LymphNode Metastasis
Lymph node metastasis is the most important prognostic
factor in clinical stage 1 endometrial cancer. Of patients
with clinical stage I disease, about 10% will have pelvic
and 6% will have para-aortic lymph node metastases [15].
Patients with lymph node metastases have an almost sixfold
higher likelihood of developing recurrent cancer compared
to patients without lymph node metastases. Morrow et al.
evaluated the relationship between surgical-pathologic risk
factors and outcomes in clinical stage I and II endometrial
cancer using the GOG 33 database [15]. They noted that
the ﬁve-year recurrence-free survival was 90% in patients
without lymph node metastases, 75% in patients with pelvic
lymph node metastases, and 38% in patients with positive
para-aortic lymph nodes. In fact, the strongest predictor of
recurrence was lymph node status. Lurain et al. subsequently
conﬁrmed an overall recurrence rate of 48% with positive
lymph nodes, including 45% with positive pelvic nodes and
64% with positive para-aortic nodes, compared to 8% with
negative nodes. The ﬁve-year disease-free survival rate for
patients with lymph node metastases was 54% compared
with 90% for patients without lymph node metastases [16].
Mariani et al. noted that just the presence or absence of para-
aorticlymphnodemetastaseswasofparamountimportance.
Of para-aortic node-positive patients, 58% developed pro-
gressiveorrecurrentcancer,and90%ofpatientswithapara-
aortic recurrence died of disease [17].
Mariani et al. evaluated patients with lymph node
metastases in addition to other extrauterine sites of disease
(vagina, uterine serosa, positive peritoneal cytology, and
adnexal involvement). The recurrence rate was 32% (5%
extranodal) for those with lymphatic dissemination only
comparedto67%(41%extranodal)forthosewithadditional
sites of extrauterine disease spread [18]. Similarly, Lurain et
al. noted that patients with lymph node metastases who also
had involvement of the uterine serosa, positive peritoneal
cytology, and/or adnexal metastasis had a two-year overall
survivalof50%comparedto88%inpatientswithonlynodal
extrauterine disease [16].
At Northwestern, we evaluated the clinicopathologic
characteristics and survival of patients with pelvic and para-
aortic lymph node metastases [19]. Five-year disease-speciﬁc
survival was 72%, and ﬁve-year overall survival was 61%,
including 70% for those with pelvic node metastases only
and 49% for those with para-aortic metastases. On mul-
tivariate analysis, advancing patient age, nonendometrioidInternational Journal of Surgical Oncology 3
histology, and ≥50% myometrial invasion were signiﬁcantly
associated with poorer overall survival. Disease recurred in
25% of patients, and all recurrences were outside of the
adjuvant radiation ﬁeld.
4. Therapeutic Value of Lymph Node Dissection
Several retrospective studies have lent credence to the idea
that surgical staging with lymph node dissection can not
only assist with directing postoperative adjuvant therapy,
but may even have a therapeutic eﬀect. Havrilesky et al. in
2005 found that in a group of patients with pelvic or para-
aortic metastases, disease-speciﬁc survival was improved if
microscopic versus gross disease was removed [20]. This
group also noted that gross nodal disease not debulked
was a signiﬁcant poor prognostic factor in these patients.
In patients with IIIC endometrial cancer, lymph node
involvement is a poor prognostic factor, and there appears
to be a therapeutic beneﬁt to lymph node dissection and
resection in these patients. In a group of patients with FIGO
stage I and II endometrial cancer, Lutman et al. found that
pelvic lymph node count was an important prognostic factor
in patients with grade 3 tumors and clear cell or papillary
serous histology [21]. The authors also stratiﬁed patients by
risk factors including myometrial invasion, histology, and
age, and they found that a pelvic lymph node count of ≥12
was an important prognostic factorfor survival in patients of
high-intermediaterisk(age>70with1riskfactoror<70with
2riskfactors).Fromthispaper,itappearsthatapelviclymph
node count ≥12 was associated with improved survival in
patients of high-intermediate risk and in patients with stage
I and II endometrial cancer with high-risk histology.
In a comparison of patients with endometrial cancer
in the SEER database, Chan et al. found that in the
intermediate/high-risk patients (Stage IB, grade 3; Stage IC
and II-IV, all grades), lymph node dissection was associated
with improved 5-year disease-speciﬁc survival. Extensive
nodal resection also improved disease-speciﬁc survival in
stage IIIC-IV patients. There was no survival beneﬁt seen in
patients with low-risk disease [22]. Chan et al. also studied
data from the National Cancer Institute database on close
to 40,000 women with endometrioid endometrial cancer
[23]. Comparing women who underwent surgical staging
with lymph node dissection with those who did not have
a lymph node dissection, they noted 5-year disease-speciﬁc
survival for women with disease stages I, II, III, IV who
underwent lymphadenectomy of 96%, 90%, 74%, and 53%
as compared to women not undergoing lymphadenectomy
of 97%, 82%, 63%, and 27%, respectively for each stage. No
survival beneﬁt was noted for women with stage I, grade 1
disease. Similarly, Neubauer et al. found no survival beneﬁt
to lymph node dissection in patients with preoperative grade
1 endometrial cancer [24]. They also noted that pelvic and
para-aortic node metastases were identiﬁed in 5.4% and
3.2%,respectively,ofpatientsundergoinglymphadenectomy
and that 25% of patients were upgraded on ﬁnal pathology,
including 22% upgraded to grade 2 and 3% upgraded to
grade 3.
Three other retrospective studies have suggested a thera-
peutic beneﬁt to lymphadenectomy. Kilgore et al. evaluated
survival in 649 patients who underwent surgery for clinical
stage I or II endometrial adenocarcinoma. After three years
of mean followup, patients undergoing multiple-site pelvic
lymph node dissection had improved overall 5-year survival
as compared to patients who did not undergo lymph node
dissection, 90% versus 70% [25]. In patients at high risk
of para-aortic node metastases (myometrial invasion >50%,
positive pelvic lymph nodes, or adnexal involvement), Mari-
ani et al. noted an improved survival in patients undergoing
para-aortic lymphadenectomy as compared to those who did
not undergo para-aortic lymph node dissection [17]. The
5-year progression-free survival was 36% in those who did
not undergo staging with para-aortic lymph node dissection
versus 76% in those undergoing para-aortic lymph node
dissection; the overall survival was improved as well (42%
versus 77%). Similarly, Todo et al. noted that overall
survival was longer in patients with endometrial cancer
undergoing pelvic and paraaortic lymphadenectomy versus
pelvic lymphadenectomy alone (HR 0.53) [26]. In patients at
intermediate to high risk of recurrence (IA grade 3, IB and
IC any grade, stage II–IV disease), a more pronounced eﬀect
was noted for pelvic and para-aortic lymphadenectomy with
longer overall, disease-speciﬁc, and recurrence-free survival
noted in the group of these patients undergoing both pelvic
and para-aortic lymphadenectomy as compared to pelvic
lymphadenectomiesalone.A10.6%increasein5-yearoverall
survival was noted in intermediate to high-risk patients
undergoingbothpelvicandpara-aorticlymphadenectomies.
Lymphnodedissectionmayalsoassistwithpostoperative
treatment planning in patients with endometrial cancer. In
a retrospective review of 349 patients undergoing surgical
management for endometrial cancer, Ben-Shachar et al.
discovered that 12% of patients received adjuvant therapy
postoperatively but that based upon the results of surgical
staging 17% were able to avoid adjuvant therapy [27].
Thus, in an otherwise high-risk patient, the use of adjuvant
radiation or chemotherapy may be averted based upon the
results of surgical staging including lymph node dissection.
Selvaggi et al. also found that surgical staging identiﬁed
patients with positive lymph nodes who would not have
otherwise received postoperative radiation, but they also
found that the pattern and location of recurrences was not
diﬀerent between patients undergoing and not undergoing
lymphadenectomy [28].
The question remains as to whether lymph node dissec-
tion confers a survival beneﬁt to patients. A large number of
patients would be required to reliably answer this question,
as most patients with endometrial cancer survive more than
ﬁve years and often die of comorbidities ﬁrst. Bernardini et
al. performed another retrospective review comparing the
surgical practices of two academic centers with regard to
surgical staging of grade 1 endometrial cancer [29]. 494
women were included in the study and were similar in
terms of grade, ﬁnal histology, and type of hysterectomy.
Patients in the institution that did not routinely perform
surgical staging with lymph node dissection were on average
older, more likely to have lymphovascular space invasion,4 International Journal of Surgical Oncology
andcervicalinvolvement.Lymphadenectomywasperformed
in 49.4% versus 11.7% of patients in the institution that
did not routinely perform surgical staging. Overall survival
was similar at both institutions (96% versus 96%), and
three-year recurrence-free survival was also similar. Thus in
low-risk endometrial cancer, there may be no diﬀerence in
recurrence-free or overall survival within the ﬁrst ﬁve years
of surgical management.
5.ProspectiveDataRegarding
Therapeutic Beneﬁt of Lymph Node
DissectioninEndometrial Cancer
Two prospective randomized trials have recently been pub-
lished which shed more light onto the topic of lymph
node dissection, in endometrial cancer. The ASTEC study
was a randomized controlled trial involving 85 institutions
i n4c o u n t r i e s[ 30]. 1408 patients were randomized to
abdominal hysterectomy, bilateral salpingo-oophorectomy
with or without pelvic lymph node dissection and then
subsequently to the use of postoperative radiation. The study
was designed to detect an improvement in overall 5-year
survivalfrom80%inthestandardarmto90%inthepatients
undergoing lymphadenectomy. There was no diﬀerence in
overall survival between the two treatment groups. The
study has been criticized due to noncompliance with regard
to lymph node dissection as well as the small average
number of lymph nodes removed. In addition, some patients
were randomized to postoperative radiation irrespective of
surgical pathology, which may have skewed survival data.
Panici et al. reported on a phase 3 randomized trial
comparing standard surgery of total hysterectomy with bilat-
eral salpingo-oophorectomy with or without planned lymph
node dissection for early-stage endometrial carcinoma [31].
In this study, the median number of lymph nodes removed
was twenty-eight and patients were comparable in their
characteristics across both arms. A greater number of lymph
node metastases was detected in the lymphadenectomy
arm (13.3% versus 3.2%), and early and late postopera-
tive complications occurred statistically more frequently in
the lymphadenectomy arm. Similar proportions of women
in both groups received adjuvant therapy (68.9% versus
64.8%). Of patients developing recurrent cancer, median
time to relapse was similar in both groups (14 months versus
13 months), and overall 5-year survival was not signiﬁcantly
diﬀerent (85.9% in the lymph node dissection arm versus
90% in the standard surgery alone arm). This study did not
have standard criteria for the use of postoperative adjuvant
therapy and did not consider recurrence risk in the analysis
of survival.
Both of these studies found that lymphadenectomy did
not confer a survival advantage in a low-risk group of
endometrial cancer patients, but that lymphadenectomy did
allow for more accurate staging with a signiﬁcant number
of patients upstaged in the Panici et al. study. Both studies
were limited in that postoperative adjuvant therapy was
not controlled and pelvic lymphadenectomy alone was
performed instead of a systematic pelvic and para-aortic
lymphadenectomy. Both studies came to similar conclu-
sions,supportingpreviouslygatheredretrospectivedata,that
patients with endometrial cancer and low-risk factors for
recurrence may not require a systematic lymphadenectomy
in contrast to patients with intermediate or high-risk factors
for recurrence.
6. Long-Term Risks of Lymph Node Dissection
A longstanding argument against routine pelvic lymph
node dissection is that the procedure can involve risks for
the patient including vascular injury intraoperatively, but
more importantly, long-term risks such as lymphedema and
lymphocyst. In an analysis of the surgical complications
associated with surgical staging in 128 patients, Orr et al.
determined the long-term risk of lymphocyst to be 1.3%
and lymphedema to be 0.7%, both acceptable risks for a
surgical procedure which can assist a physician with the
quantiﬁcationofapatient’sriskforrecurrence[32].Recently,
Todo et al. performed a retrospective chart review evaluating
therisk factorsassociatedwithpostoperative lowerextremity
lymphedema and found that 38% of patients undergo-
ing exploratory laparotomy, total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and pelvic and para-aortic
lymph node dissection experienced postoperative lower
extremity lymphedema, a much higher percentage than
cited in other studies. The authors found that adjuvant
pelvic external beam radiation therapy, resection of more
than thirty-one lymph nodes, and removal of circumﬂex
iliac nodes were risk factors for the development of lower
extremity lymphedema [33].
As more patients undergo minimally invasive surgery for
the treatment of endometrial cancer there is the question of
whether or not laparoscopic surgery can decrease the risk
of postoperative complications including lymphedema and
lymphocele. Kong et al. also compared the surgical outcomes
of laparoscopic surgery and open surgery in patients with
endometrial cancer [34]. Patients undergoing laparoscopy
had on average 4 more lymph nodes removed and 11.7%
of these patients were diagnosed with a lymphocyst while
10% of patients undergoing laparotomy were diagnosed
with a lymphocyst. Again, the risk of lymphedema and
lymphocystes appears to be related to the number of lymph
nodes removed. The percentage of patients experiencing
lymphedema varies within the literature and has increased in
prevalence,butthismaysimplybeduetogreaterattentionto
this postoperative complication.
Several studies have veriﬁed the minimally invasive
approachtothesurgicaltreatmentofendometrialcancerand
support the notion that laparoscopy may beneﬁt patients,
especially those at high risk for postoperative complications
[35, 36]. Two prospective randomized trials have also proven
the safety of laparoscopy in the treatment of endome-
trial cancer [36, 37]. The Gynecologic Oncology Group
LAP2 study compared surgical complications and short-
term outcomes in 2616 patients with clinical stage I-IIA
endometrial cancer randomly assigned to laparotomy (920)
or laparoscopy (1696) [37]. All patients were to undergoInternational Journal of Surgical Oncology 5
standardized surgical staging. Intraoperative complications
were similar between the two groups (8% for laparotomy
and10%forlaparoscopy),whilepostoperativecomplications
were more common in laparotomy patients (21% versus
14%). Pelvic lymph node dissection was performed in 99%
of laparotomy patients and 98% of laparoscopy patients.
No prospective studies exist which directly compare post-
operative lymphedema and lymphocyst rates as a primary
endpoint in patients undergoing lymphadenectomy for
endometrial cancer; however, LAP2 proved that a minimally
invasive approach to surgical staging of endometrial cancer
is a reasonable alternative to the standard exploratory
laparotomy [37], while the trial by Tozzi et al. proved that
survival of patients with endometrial cancer undergoing





In light of the above survival ﬁndings of both retrospective
and prospective trials, it seems that a group of low-risk
patients exist who may not need routine lymph node
dissection. Mariani et al. at the Mayo Clinic published an
algorithm for performing lymph node dissection in patients
with endometrial cancer [38]. Patients not requiring lymph
nodedissectionarethosewitha2cmorsmallertumor,grade
1 or 2 disease, endometrioid histology, myometrial invasion
of 50% or less, and no evidence of gross metastatic disease.
The authors found that by using this algorithm, no patient
in the low-risk group had nodal metastasis. This model may
only work, however, in select centers that have access to a
dedicated gynecologic pathologist who can provide accurate
intraoperative assessment thereby decreasing the chance of
signiﬁcant upstaging. Lee et al. constructed a preoperative
prediction model to help determine which patients can avoid
lymph node dissection in order to bypass the need for a
pathologist at the time of intraoperative assessment [39].
Eligible patients were those who underwent surgical staging
and lymph node dissection for endometrial cancer. Preoper-
ative predictors comprising the scoring system included CA-
125, MRI to assess myometrial invasion, histologic grade,
and clinical stage. Patients in the low-risk group (score of
0-1) had no nodal metastases, whereas patients in the high-
risk group (score 3-4) had a frequency of nodal metastasis
of 50%. These studies argue for the triage of endometrial
cancer patients into low-risk and high-risk groups, thereby
sparing low-risk patients from undergoing a full lymph node
dissection.
Another future development in surgical staging of
endometrialcancermaylieinsentinellymphnodedetection.
Several studies have validated the use of sentinel lymph node
detection in experienced hands in other gynecologic cancers.
Similarly in endometrial cancer, authors have noted that
the sentinel node detection rate ranges from 77% to 94%
depending on provider experience level and that the false
negative rate decreases with increasing provider experience
[40]. Khoury-Collado et al. evaluated the sentinel lymph
node detection rate after cervical injection of blue dye and
found that the detection rate at the beginning of the study
was much lower than at the end of the study (78% versus
94%) [41]. Several methods of injection of dye have been
evaluated and none have proven superior thus far. Mais et al.
compared the sentinel node detection rate in patients with
clinical stage I-II endometrial cancer randomized to either
exploratory laparotomy or laparoscopically assisted vaginal
hysterectomy [42]. The authors found that the sentinel
lymph node detection rate was higher in laparoscopic
procedures (82%) versus laparotomy (41%), but that overall
only 50% of patients with lymph node metastases were
detected. Sentinel lymph node detection cannot as of yet
be considered equal to a complete lymphadenectomy in
endometrial cancer. Larger studies are needed to determine
the best method of dye injection, the optimal patient this
procedure will beneﬁt, and the eﬃcacy of sentinel lymph
node detection in endometrial cancer.
In the near future, the oncology community may also
use molecular markers to predict the metastatic potential of
endometrialcancer.MutationsinthePTENgenecausingloss
of function have been reported in 25–83% of endometrioid
carcinomas. P53 mutations have also been reported in
endometrial carcinomas, more often in papillary serous
histology. Overexpression of P53, altered P16 expression,
and high Ki-67 expression have all been associated with
a poor prognosis, while mutations or deletions of the
PTEN gene tend to be associated with well-diﬀerentiated
and less invasive tumors [43]. The DNA ploidy index is
another molecular prognostic factor which may predict
the aggressiveness of an endometrial cancer [44]. Type 2
endometrial carcinomas are more likely to be nondiploid,
while endometrioid carcinomas are more likely to be
diploid. DNA ploidy may prove useful preoperatively to help
determine which patients are at higher risk of lymph node
metastasis and postoperatively to determine which patients
are more likely to need adjuvant therapy.
In an attempt to further determine preoperatively which
patients with endometrial cancer are more likely to need a
lymphadenectomy, Trovik et al. examined stathmin expres-
sion which is tied to the AKT signaling pathway [45].
Stathmin expression was correlated with non-endometrioid
histology,aneuploidy,andhighergrade.Stathminexpression
was also found to be an independent predictor of lymph
nodemetastases.Clearly,molecularmarkersareusefulatthis
time to predict tumor aggressiveness and nonendometrioid
histology but further studies are needed to ﬁnd a marker
that can predict lymph node metastases in grade 1 or 2
endometrioid carcinomas.
8. Conclusion
After review of the literature, we conclude that surgical
staging not only identiﬁes most patients with extrauterine
disease, but also identiﬁes patients with uterine risk factors
for recurrence, including large tumor size, deep myometrial
invasion, LVSI, cervical extension, and positive peritoneal6 International Journal of Surgical Oncology
cytology.Identiﬁcationoftheseextrauterineandintrauterine
risk factors allows for a more informed approach to the
use of postoperative adjuvant therapy. A systematic lymph
node dissection should be performed in patients with
endometrial cancer who are at intermediate to high risk
of lymph node metastases. Lymph node biopsies are not
required in patients assessed intraoperatively to be at very
low risk for lymphatic metastasis (i.e., patients with small
(<2cm) grade 1 endometrial cancers with only superﬁcial
myometrial invasion). There are documented risks asso-
ciated with lymphadenectomy, but these risks decrease in
the hands of an experienced surgeon. It is hoped that
this approach of surgical staging followed by postoperative
targeted treatment will improve survival and spare patients
unnecessary exposure to radiation and/or chemotherapy.
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